Fact checked byKristen Dowd

Read more

October 11, 2024
2 min read
Save

Bimekizumab maintains scalp, palmoplantar psoriasis clearance through 4 years

Fact checked byKristen Dowd
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Complete scalp and palmoplantar psoriasis clearance was achieved by 85.6% and 86.6% of patients at 1 year.
  • After 4 years of treatment, 79.5% and 88.7% maintained these results.

Patients with scalp and palmoplantar psoriasis treated with bimekizumab had a high rate of clearance maintained through 4 years of treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

“Scalp and palmoplantar psoriasis and psoriatic changes in the nails can have a large impact on functional ability and health-related quality of life; these are referred to as high-impact areas,” Joseph F. Merola, MD, MMSc, chair of dermatology at the University of Texas Southwestern, and colleagues wrote.

Scalp psoriasis 2
Patients with scalp and palmoplantar psoriasis treated with bimekizumab had a high rate of clearance maintained through 4 years of treatment. Image: Adobe Stock.

The 3-year, open-label extension BE BRIGHT study included patients from the phase 3 BE VIVID, BE SURE and BE READY trials. Patients received bimekizumab (Bimzelx, UCB) 320 mg every 4 weeks to week 16 and then every 4 or 8 weeks throughout the trial. These data are pooled from all trials.

At 1 year, 85.6% of all bimekizumab-treated patients achieved scalp IGA 0 and 86.6% achieved palmoplantar IGA 0, with 79.5% and 88.7% maintaining these results at year 4, respectively.

In patients who received treatment every 8 weeks after the initial 16-weeks of every 4-week dosing (Q4W/Q8W), scalp IGA 0 was achieved by 94.7% at year 1 and 86.8% at year 4, whereas palmoplantar IGA 0 was reached by 91.7% at year 1 and 83.4% at year 4.

A clear score on the modified Nail Psoriasis Severity Index was achieved by 58.8% and 61.6% of all bimekizumab-treated patients at years 1 and 4, with those in the Q4W/Q8W group seeing 59.7% reach this goal at year 1 and 67.4% at year 4.

“A high percentage of bimekizumab-treated patients achieved and maintained complete clearance of scalp and palmoplantar psoriasis over 4 years,” the authors wrote. “Most achieved complete nail clearance by year 1, with rates numerically increasing to year 2 and remaining high through year 4.”

Reference: